Sign inJoin waitlistJoin the waitlist

Charles Peyton

Director of Clinical Trials · University of Alabama Hospital

Credentials: · · · ·

History

University of Alabama Hospital
Present
University of Alabama Hospital
Present

University of South Florida Morsani College of Medicine
2026–2027
Urology
University of Alabama Hospital
2021–2026
Med Univ of South Carolina Coll of Med
2007–2011

Research

NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network · 2024 · 226 citations
Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer
JAMA Oncology · 2018 · First of 13 authors · 121 citations
Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia
The Journal of Urology · 2013 · 59 citations

PS
Philippe Spiess
27 papers
MA
Mounsif Azizi
22 papers
Wade Sexton
18 papers
SG
Scott Gilbert
14 papers
Juan Chipollini
11 papers · 9 as a fellow
Murat Aydin
9 papers
Ali Hajiran
7 papers · 7 as a resident
Brandon Manley
7 papers
Viraj Master
7 papers
Soroush Rais-Bahrami
6 papers
Alejandro Rodriguez
5 papers
Andrew Fang
5 papers · 4 as a resident

Clinical trials

Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
Principal investigator · Recruiting · Phase 2
University of Alabama at Birmingham
2024–2028
Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort (CystoDiscomfort)
Site PI · Not yet recruiting · Phase 3
Florian Schroeck
2026–2031
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2028